AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2022
Jun 10, 2022
32312_dirs_2022-06-10_d32604d4-fce8-42b1-a74a-e4814236da79.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2022-06-08
Reporting Person: Nussbaum Ran (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-06-08 | Stock Option (right to buy) | $7.06 | A | 6817 | Acquired | 2032-06-08 | Ordinary Shares (6817) | Indirect |
| 2022-06-08 | Stock Option (right to buy) | $7.06 | A | 3183 | Acquired | 2032-06-08 | Ordinary Shares (3183) | Indirect |
Footnotes
F1: The shares underlying the stock option will vest in equal quarterly installments over a period of one year.
More from UroGen Pharma Ltd.
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11
Director's Dealing
2026
Feb 4